Man­u­fac­tur­ing roundup: Cel­l­Vax part­ners up with Ther­a­gent for PhII tri­al; Ox­ford Bio­med­ica sells fa­cil­i­ty for $70M+

The cell ther­a­py CD­MO Ther­a­gent has roped in a man­u­fac­tur­ing con­tract for a Phase II tri­al.

The com­pa­ny is work­ing on Cel­l­Vax Ther­a­peu­tics’ im­munother­a­py can­di­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER